Haleon (HLN) Cash from Financing Activities (2021 - 2023)
Haleon (HLN) recorded quarterly Cash from Financing Activities of -$841.5 million in Q4 2023, down 108.39% on a QoQ basis from $10.0 billion in Q4 2022, and down 108.39% year-over-year from $10.0 billion in Q4 2022.
Haleon (HLN) Cash from Financing Activities (2021 - 2023) Analysis & Trends
Haleon has disclosed Cash from Financing Activities across 3 years of filings, most recently posting -$841.5 million for Q4 2023.
- Quarterly Cash from Financing Activities fell 108.39% year-over-year to -$841.5 million in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $18.7 billion (changed N/A YoY) and the FY2025 annual result came in at -$4.1 billion, down 110.93% from the prior year.
- Cash from Financing Activities declined to -$841.5 million in Q4 2023, from $10.0 billion in the prior quarter.
- Over five years, Cash from Financing Activities peaked at $10.5 billion in Q3 2022 and troughed at -$965.2 million in Q4 2021.
- A 3-year average of $4.7 billion and a median of $4.6 billion in 2022 frame the typical range for Cash from Financing Activities.
- Annual changes were most pronounced in 2022 — Cash from Financing Activities surged 1138.55% — and 2023, when it slumped 108.39%.
- Tracing HLN's Cash from Financing Activities over 3 years: stood at -$965.2 million in 2021, then jumped by 1138.55% to $10.0 billion in 2022, then sank by 108.39% to -$841.5 million in 2023.
- Business Quant data shows HLN's Cash from Financing Activities at -$841.5 million in Q4 2023, $10.0 billion in Q4 2022, and $10.5 billion in Q3 2022.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 13.00 Mn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | -840.00 Mn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | -1.48 Bn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | - |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | -86.10 Mn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | -65.00 Mn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | 1.47 Bn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | -77.88 Mn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | -11.62 Mn |
| 10 | Haleon | 1.09 Bn | -773.69 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | -841.50 Mn |
| Dec 31, 2023 | -841.50 Mn |
| Dec 31, 2022 | 10.02 Bn |
| Dec 31, 2022 | 10.02 Bn |
| Sep 20, 2022 | 10.52 Bn |
| Sep 20, 2022 | 10.52 Bn |
| Dec 31, 2021 | -965.18 Mn |
| Dec 31, 2021 | -965.18 Mn |